alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
**EXHIBIT 32.2**

**CERTIFICATION PURSUANT TO18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection withthe accompanying Quarterly Report on Form 10-Q/A of Southwall TechnologiesInc. (the “Company”), for the quarter ended March 28, 2004, as filed withthe Securities and Exchange Commission on the date hereof (the “Report”), I,Maury Austin, the Chief Financial Officer of the Company, hereby certifypursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906of the Sarbanes-Oxley Act of 2002, that:

1)   The Report fully complies with therequirements of Section 13(a) or 15(d) of the SecuritiesExchange Act of 1934; and

2)   theinformation contained in the Report fairly presents, in all material respects,the financial condition and results of operations of the Company.
|        | September 7, 2004 | By:                       | /s/ Maury  Austin |   |
|--------|------------------------|---------------------------|-------------------|--------|
|   |                   | Maury Austin              |
|   | * *               | *Chief Financial Officer* |

 

A signed original of this written statement requiredby Section 906, or other document authenticating, acknowledging orotherwise adopting the signature that appears in typed form within theelectronic version of this written statement required by Section 906, hasbeen provided to the Company and will be retained by the Company and furnishedto the Securities and Exchange Commission or its staff upon request.

In accordance with Item 601 of Regulation S-K, thiscertification is being “furnished” as Exhibit 32.2 to the Company’squarterly report and shall not be deemed “filed” for purposes of Section 18of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwisesubject to the liabilities of that section, nor shall it be deemed incorporatedby reference in any filing under the Securities Act of 1933 or the ExchangeAct, except as expressly set forth by specific reference in such a filing.

----
# L_2018316EN.01000401.xml

| 13.12.2018 | EN | Official Journal of the European Union | L 316/4 |
| --- | --- | --- | --- |

13.12.2018

EN

Official Journal of the European Union

L 316/4

---

COMMISSION IMPLEMENTING REGULATION (EU) 2018/1965

of 6 December 2018

conferring protection under Article 99 of Regulation (EU) No 1308/2013 of the European Parliament and of the Council on the name ‘Uhlen Roth Lay’ (PDO)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EU) No 1308/2013 of the European Parliament and of the Council of 17 December 2013 establishing a common organisation of the markets in agricultural products and repealing Council Regulations (EEC) No 922/72, (EEC) No 234/79, (EC) No 1037/2001 and (EC) No 1234/2007 (1), and in particular Article 99 thereof,

Whereas:

| (1) | In accordance with Article 97(2) and (3) of Regulation (EU) No 1308/2013, the Commission has examined the application to register the name ‘Uhlen Roth Lay’ sent by Germany and has published it in the Official Journal of the European Union (2). |
| --- | --- |

(1)

In accordance with Article 97(2) and (3) of Regulation (EU) No 1308/2013, the Commission has examined the application to register the name ‘Uhlen Roth Lay’ sent by Germany and has published it in the Official Journal of the European Union (2).

| (2) | No statement of objection has been received by the Commission under Article 98 of Regulation (EU) No 1308/2013. |
| --- | --- |

(2)

No statement of objection has been received by the Commission under Article 98 of Regulation (EU) No 1308/2013.

| (3) | In accordance with Article 99 of Regulation (EU) No 1308/2013, the name ‘Uhlen Roth Lay’ should be protected and entered in the register referred to in Article 104 of that Regulation. |
| --- | --- |

(3)

In accordance with Article 99 of Regulation (EU) No 1308/2013, the name ‘Uhlen Roth Lay’ should be protected and entered in the register referred to in Article 104 of that Regulation.

| (4) | The measures provided for in this Regulation are in accordance with the opinion of the Committee for the Common Organisation of the Agricultural Markets, |
| --- | --- |

(4)

The measures provided for in this Regulation are in accordance with the opinion of the Committee for the Common Organisation of the Agricultural Markets,

HAS ADOPTED THIS REGULATION:

Article 1

The name ‘Uhlen Roth Lay’ (PDO) is hereby protected.

Article 2

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 6 December 2018.

For the Commission,

On behalf of the President,

Phil HOGAN

Member of the Commission

---

(1)  
  OJ L 347, 20.12.2013, p. 671.

1

(2)  
  OJ C 277, 7.8.2018, p. 8.

2

---
§ 207.41 Who must list drugs and what drugs must they list? ( a ) Each registrant must list each drug that it manufactures, repacks, relabels, or salvages for commercial distribution. Each domestic registrant must list each such drug regardless of whether the drug enters interstate commerce. When operations are conducted at more than one establishment, and common ownership and control exists among all the establishments, the parent, subsidiary, or affiliate company may submit listing information for any drug manufactured, repacked, relabeled, or salvaged at any such establishment. A drug manufactured, repacked, or relabeled for private label distribution must be listed in accordance with paragraph (c) of this section.
( b ) Registrants must provide listing information for each drug in accordance with the listing requirements described in §§ 207.49, 207.53, and 207.54 that correspond to the activity or activities they engage in for that drug.
( c ) ( 1 ) For both animal and human drugs, each registrant must list each drug it manufactures, repacks, or relabels for commercial distribution under the trade name or label of a private label distributor using an NDC that includes such private label distributor's labeler code.
( 2 ) Additionally, in the case of human drugs, each registrant must list each human drug it manufactures, repacks, or relabels using an NDC that includes the registrant's own labeler code, regardless of whether the drug is commercially distributed under the registrant's own label or trade name or under the label or trade name of a private label distributor.
# L_2019019EN.01000701.xml

| 22.1.2019 | EN | Official Journal of the European Union | L 19/7 |
| --- | --- | --- | --- |

22.1.2019

EN

Official Journal of the European Union

L 19/7

---

COUNCIL DECISION (CFSP) 2019/95

of 21 January 2019

amending Decision 2014/145/CFSP concerning restrictive measures in respect of actions undermining or threatening the territorial integrity, sovereignty and independence of Ukraine

THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Treaty on European Union, and in particular Article 29 thereof,

Having regard to the proposal of the High Representative of the Union for Foreign Affairs and Security Policy,

Whereas:

| (1) | On 17 March 2014, the Council adopted Decision 2014/145/CFSP. (1) |
| --- | --- |

(1)

On 17 March 2014, the Council adopted Decision 2014/145/CFSP. (1)

| (2) | Following the death of a designated person, the Council considers that the entry for this person should be deleted from the Annex to Decision 2014/145/CFSP. |
| --- | --- |

(2)

Following the death of a designated person, the Council considers that the entry for this person should be deleted from the Annex to Decision 2014/145/CFSP.

| (3) | Decision 2014/145/CFSP should therefore be amended accordingly, |
| --- | --- |

(3)

Decision 2014/145/CFSP should therefore be amended accordingly,

HAS ADOPTED THIS DECISION:

Article 1

The Annex to Decision 2014/145/CFSP is amended as set out in the Annex to this Decision.

Article 2

This Decision shall enter into force on the day following that of its publication in the Official Journal of the European Union.

Done at Brussels, 21 January 2019.

For the Council

The President

F. MOGHERINI

---

(1)  Council Decision 2014/145/CFSP of 17 March 2014 concerning restrictive measures in respect of actions undermining or threatening the territorial integrity, sovereignty and independence of Ukraine (OJ L 78, 17.3.2014, p. 16).

1

---

ANNEX

The entry concerning the following person is deleted from the list set out in the Annex to Decision 2014/145/CFSP:

| ‘150. | Iosif (Joseph) Davydovich KOBZON’ |
| --- | --- |

‘150.

Iosif (Joseph) Davydovich KOBZON’

---
Exhibit 32.2

                         AMCOL INTERNATIONAL CORPORATION

                   Certification of Periodic Financial Report
                       Pursuant to 18 U.S.C. Section 1350

     Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of
the Sarbanes-Oxley Act of 2002, the undersigned officer of AMCOL International
Corporation (the "Company") certifies that the Quarterly Report on Form 10-Q of
the Company for the quarter ended September 30, 2003 fully complies with the
requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934
and information contained in that Form 10-Q fairly presents, in all material
respects, the financial condition and results of operations of the Company.




Dated: November 12, 2003                        /s/ Lawrence E. Washow
                                                ----------------------
                                                Lawrence E. Washow
                                                Chief Executive Officer

         A signed original of this written statement required by Section 906 has
been provided to AMCOL International Corporation and will be retained by AMCOL
International Corporation and furnished to the Securities and Exchange
Commission or its staff upon request.

<PAGE>

                         AMCOL INTERNATIONAL CORPORATION

                   Certification of Periodic Financial Report
                       Pursuant to 18 U.S.C. Section 1350

     Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of
the Sarbanes-Oxley Act of 2002, the undersigned officer of AMCOL International
Corporation (the "Company") certifies that the Quarterly Report on Form 10-Q of
the Company for the quarter ended September 30, 2003 fully complies with the
requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934
and information contained in that Form 10-Q fairly presents, in all material
respects, the financial condition and results of operations of the Company.


Dated: November 12, 2003                /s/  Gary L. Castagna
                                        ---------------------
                                        Gary L. Castagna
                                        Senior Vice President, Chief Financial
                                        Officer and Principal Accounting Officer

     A signed original of this written statement required by Section 906 has
been provided to AMCOL International Corporation and will be retained by AMCOL
International Corporation and furnished to the Securities and Exchange
Commission or its staff upon request.
#### § 3.1 Purpose.

This regulation relates to agency management and organization and has two purposes. The first is to implement section 503(g) of the act, as added by section 16 of the Safe Medical Devices Act of 1990 (Public Law 101-629) and amended by section 204 of the Medical Device User Fee and Modernization Act of 2002 (Public Law 107-250), by specifying how FDA will determine the organizational component within FDA designated to have primary jurisdiction for the premarket review and regulation of products that are comprised of any combination of a drug and a device; a device and a biological; a biological and a drug; or a drug, a device and a biological. This determination will eliminate, in most cases, the need to receive approvals from more than one FDA component for such combination products. The second purpose of this regulation is to enhance the efficiency of agency management and operations by providing procedures for determining which agency component will have primary jurisdiction for any drug, device, or biological product where such jurisdiction is unclear or in dispute. Nothing in this section prevents FDA from using any agency resources it deems necessary to ensure adequate review of the safety and effectiveness of any product, or the substantial equivalence of any device to a predicate device.

[56 FR 58756, Nov. 21, 1991, as amended at 68 FR 37077, June 23, 2003]
Exhibit 31.2



I, Michael
Schwanbeck, certify that:



1. I
have reviewed this annual report on Form 10-K for fiscal year 2017 of American Cannabis Company, Inc.;



2. Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
to the period covered by this report;



3. Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented
in this report;



4. The
registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:



(a) Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in which this report is being prepared;



(b) Evaluated
the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such
evaluation; and



(c) Disclosed
in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s
most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and



5. The
registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over
financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or
persons performing the equivalent functions):



(a) All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and



(b) Any
fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s
internal control over financial reporting.





| | By:                               | /s/
                                         J. Michael Schwanbeck
| | --------------------------------- | ------------------------------------------------------------------
| | J. Michael
    Schwanbeck        
| | Chief
    Financial Officer      
| | (Principal
    Financial Officer)



Date:
December 26, 2018



33
Editorial Note on Part 189
Editorial Note: Nomenclature changes to part 189 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; 70 FR 40880, July 15, 2005; and 70 FR 67651, Nov. 8, 2005.

§ 189.175 P-4000. ( a ) P-4000 is the chemical 5-nitro-2-n-propoxyaniline, C9H12N2O3. It is a synthetic chemical having a sweet taste about 4000 times that of sucrose, is not found in natural products at levels detectable by the official methodology, and has been proposed for use as an artificial sweetener.
( b ) Food containing any added or detectable level of P-4000 is deemed to be adulterated in violation of the act based upon an order published in the Federal Register of January 19, 1950 (15 FR 321).
( c ) The analytical methods used for detecting P-4000 in food are in sections 20.177-20.181 of the “Official Methods of Analysis of the Association of Official Analytical Chemists,” 13th Ed. (1980), which is incorporated by reference. Copies may be obtained from the AOAC INTERNATIONAL, 481 North Frederick Ave., suite 500, Gaithersburg, MD 20877, or may be examined at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
[42 FR 14659, Mar. 15, 1977, as amended at 49 FR 10114, Mar. 19, 1984; 54 FR 24900, June 12, 1989]
Advisory Committee 

for the 

Sustained National Climate Assessment

National Climate Assessment

Under the Global Change Research Act of 1990, the U.S. Global Change 

Research Program (USGCRP) is responsible for the quadrennial National 

Climate Assessment (NCA) reports (NCA3, NCA4). The NCA integrates 

and evaluates current and projected global climate change trends, both 

human-induced and natural, and analyzes the effects of current and 

projected climate change. 

Sustained Assessment

Sustained assessment is an ongoing participatory process for engaging 

stakeholders and scientists in discovery, communication, and use of 

scientific knowledge on global change. Products of sustained assessment 

include reports, derived data and visualizations, decision support tools, 

ongoing dialogues, and other science-based resources.

Federal Advisory Committee

The Federal Advisory Committee (FAC) helps USGCRP use the expertise 

of scientists and practitioners to identify opportunities for putting in place 

additional elements of a sustained process. Represented by question marks 

in the diagram above, the FAC provides advice on making USGCRP data 

more accessible and useful to private sector/civic organizations and 

state/municipal governments for their use in planning and decisionmaking. Additionally the FAC serves as a mechanism by which USGCRP 

can engage with the outside user community. 

Initial activities

• Writing a report (due Spring 2018) with recommendations for

improving the sustained assessment process for NCA4 and beyond

including identification of core activities and derivative products,

expanded engagement, and evaluation of the process.

• Comparing available and required elements of sustained assessment (a

gap analysis) to accelerate application of available resources and

identify priorities for next steps.

Member Composition

In 2015, the National Oceanic and 

Atmospheric Administration (NOAA) 

established the Advisory Committee for the 

Sustained National Climate Assessment 

under the provisions of the Federal Advisory 

Committee Act (FACA).

The Federal Advisory Committee has a 

diverse membership representing a wide 

range of sectors,

regions, and

expertise, including: societal responses; 

climate impacts; physical sciences; 

communications, engagement, and 

education; economics and social science; risk 

management and risk assessment; 

technology, tools and data systems. 

For more information, contact: 

Dr. Cynthia J. Decker, Designated Federal Officer

National Oceanic and Atmospheric Administration

SSMC3 Room 11230 • 1315 East-West Highway • Silver Spring, MD20910 

Phone: 301-734-1156 • Email:snca.advisorycommitee@noaa.gov

http://sncaadvisorycommittee.noaa.gov

July 2017
Exhibit 32.1  Certification of CEO

CERTIFICATIONS

I, James R. Arabia, President and Chief Executive Officer, certify that:

1.  I have reviewed this annual report on Form 10-KSB-A of Naturewell,
Incorporated;

2.  Based on my knowledge, this annual report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this annual
report;

3.  Based on my knowledge, the financial statements, and other financial
information included in this annual report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this annual report;

4.  The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

     a)  designed such disclosure controls and procedures to ensure that
material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly
during the period in which this annual report is being prepared;

     b)  evaluated the effectiveness of the registrant's disclosure controls
and procedures as of a date within 90 days prior to the filing date of this
annual report (the "Evaluation Date"); and

     c)  presented in this annual report our conclusions about the
effectiveness of the disclosure controls and procedures based on our evaluation
as of the Evaluation Date;

5.  The registrant's other certifying officers and I have disclosed, based on
our most recent evaluation, to the registrant's auditors and the audit
committee of registrant's board of directors (or persons performing the
equivalent function):

     a)  all significant deficiencies in the design or operation of internal
controls which could adversely affect the registrant's ability to record,
process, summarize and report financial data and have identified for the
registrant's auditors any material weaknesses in internal controls; and

     b)  any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls;
and

6.  The registrant's other certifying officers and I have indicated in this
annual report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.

Date:  October 15, 2003                /s/ James R .Arabia
                                       -------------------
                                           James R .Arabia
                                       President and Chief Executive Officer

_______________________________________________________________________________
Case: 16-12065 Date Filed: 05/25/2016 Page: 1 of 7 
Case: 16-12065 Date Filed: 05/25/2016 Page: 2 of 7 
Case: 16-12065 Date Filed: 05/25/2016 Page: 3 of 7 
Case: 16-12065 Date Filed: 05/25/2016 Page: 4 of 7 
Case: 16-12065 Date Filed: 05/25/2016 Page: 5 of 7 
Case: 16-12065 Date Filed: 05/25/2016 Page: 6 of 7 
Case: 16-12065 Date Filed: 05/25/2016 Page: 7 of 7